Core Points - ARCpoint Inc. has successfully closed a non-brokered private placement, raising gross proceeds of C$800,000 through the sale of 10,000,000 units at C$0.08 per unit [1] - Each unit consists of one class A subordinate voting share and one share purchase warrant, with the warrant allowing the purchase of an additional share at C$0.12 for 24 months [1] - The company plans to raise an additional C$700,000 by offering another 8,750,000 units under the same terms [5] Financial Details - The net proceeds from the offering will be allocated for operational expenses, investor awareness, investor relations, and marketing [2] - A cash commission of $36,057.60 was paid to finders, along with the issuance of 428,400 finder's shares and 536,400 finder's warrants [4] Related Party Transactions - Directors Felix Mirando and Adam Ho purchased a total of 764,199 units as part of the offering, which is classified as a related party transaction [3] - The participation of these directors is exempt from formal valuation and minority shareholder approval requirements under MI 61-101 [3] Marketing Agreement - ARCpoint has entered into a Marketing Service Agreement with Outside the Box Capital Inc., effective March 7, 2025, for marketing services [8] - The agreement includes a monthly cash fee of $25,000 USD for services aimed at increasing awareness of the company's activities [8]

Group 1 - ARC Resources achieved a record-breaking year in 2024, indicating strong performance and setting a positive outlook for 2025 and beyond [1] - The company operates in the Oil, Gas, Energy, and Metals sectors, which are central to its business strategy [1] Group 2 - The analysis emphasizes the importance of fundamental analysis, focusing on a deep "Margin of Safety" and a "Catalyst" for investment decisions [1]

For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire ServicesGreenville, South Carolina, Jan. 31, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to announce that it intends to complete a non-brokered private placement to raise gross proceeds of up to C$800,000 (the “Offering”) through the sale of up to 10,000,000 units (the “Units”) at C$0.08 per Unit. Each Unit will be comprised of one Class A Subordinate Voting Share of th ...

ONWARD ARC-EX System for spinal cord injury is now available for purchase through VA Federal Supply Schedule and GSA Advantage platforms Partnership with Lovell Government Services is providing commercial benefit, facilitating purchase through validated US government online purchasing platforms EINDHOVEN, the Netherlands, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, ...

I analyze oil and gas companies like ARC Resources and related companies in my service, Oil & Gas Value Research, where I look for undervalued names in the oil and gas space. I break down everything you need to know about these companies -- the balance sheet, competitive position and development prospects. This article is an example of what I do. But for Oil & Gas Value Research members, they get it first, and they get analysis on some companies that is not published on the free site. Interested? Sign up he ...

Company Overview - ONWARD Medical is a medical technology company focused on developing therapies to restore movement, function, and independence in individuals with spinal cord injury (SCI) and other movement disabilities [8] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the FDA [9] - ONWARD Medical is headquartered in the Netherlands, with a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts [10] Product Development and Milestones - The ARC-EX System, the first and only FDA-approved technology to improve hand strength and sensation in people with chronic spinal cord injury, achieved its first commercial sales in the US in late December 2024 [1][2] - The ARC-EX System was granted de novo classification by the FDA on December 19, 2024, and was named a 2024 TIME Magazine Best Invention [2] - The company anticipates authorization for home use of the ARC-EX System in 2025 and plans to seek CE Mark certification in early 2025, with a commercial launch in Europe expected in the second half of 2025 [5] - ONWARD Medical is also developing an implantable system called ARC-IM and an investigational ARC-BCI System, which uses a brain-computer interface powered by AI [5][9] Market and Industry Context - Spinal cord injury affects approximately seven million people worldwide, including over 300,000 in the US, with half of the injuries resulting in tetraplegia [7] - Lifetime treatment costs for tetraplegia exceed $5 million, highlighting the significant economic impact of SCI [7] - Historically, SCI has been considered permanent with limited options for functional recovery, particularly for those more than one-year post-injury [7] Commercialization and Partnerships - UW Medicine and Next Steps Chicago were among the first to purchase the ARC-EX System, aligning with the company's goal to provide access to this technology in both community rehabilitation clinics and major academic research centers [1][4] - The ARC-EX System is currently authorized for clinic use in the US, with plans to expand its availability for home use [5] - ONWARD Medical's partnerships with institutions like UW Medicine and Next Steps Chicago aim to redefine recovery and provide innovative care for individuals with SCI [4][5]

Group 1 - ARCpoint Inc. has completed the sale of its 68% ownership interest in Achieve Behavioral Health Greenville LLC for a total consideration of US$480,000, which includes US$360,000 in cash and US$120,000 in settled amounts owed [1] - The transaction is classified as a Non-Arm's Length Transaction and a related party transaction under Multilateral Instrument 61-101, but it was exempt from formal valuation and minority shareholder approval requirements [2] - ARCpoint is a US-based healthcare company that utilizes technology and physical locations to provide accessible and cost-effective healthcare solutions with transparent pricing [3]

Group 1 - ARCpoint Inc. has entered into an agreement to sell its 68% ownership interest in Achieve Behavioral Health Greenville LLC for a total consideration of US$480,000, resulting in a net cash payment of US$360,000 after deducting US$120,000 for amounts owed between the parties [1] - The sale is part of a strategy to streamline operations and provide working capital for advancing technology platform integration for CRESSO Brands franchisee locations [7] - The joint venture CRESSO Brands LLC, formed with Any Lab Test Now, combines over 235 franchise locations from ALTN and more than 135 from ARCpoint, making it the largest franchise network of its kind in the United States [2] Group 2 - Achieve Behavioral Health operates under the brand name Vertical Treatment Centers, providing drug and alcohol addiction treatment services in South Carolina [1] - ARCpoint leverages technology and physical locations to offer convenient and cost-effective healthcare solutions with transparent pricing [3]

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) ARC-EX System is the first and only FDA approved technology shown to improve hand strength and sensation after chronic spinal cord injury ARC-EX System is an FDA Breakthrough Device and 2024 TIME Magazine Best Invention EINDHOVEN, the Netherlands, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therap ...

Core Viewpoint - Nanox Imaging Ltd has received FDA clearance for its Nanox.ARC system, expanding its imaging capabilities to include pulmonary, intra-abdominal, and paranasal indications, in addition to its previous clearance for musculoskeletal imaging [2][4]. Group 1: FDA Clearance and Technology - The Nanox.ARC is a stationary X-ray system designed for general use, now cleared for multiple imaging indications [2]. - It features a proprietary digital X-ray source and advanced tomosynthesis technology, providing a three-dimensional view of the body and reducing the limitations of traditional 2D X-rays [3][4]. - The system is currently deployed in healthcare facilities across seven states in the U.S., with additional units being shipped worldwide [4]. Group 2: Impact on Healthcare Providers - The FDA clearance allows U.S. healthcare providers to access broader imaging capabilities similar to traditional X-ray devices, enhancing patient care [4]. - The technology aims to reduce patient wait times and improve overall diagnostic efficiency, potentially allowing for faster care without the need for separate imaging facilities [5][6]. - The system is designed for integration into existing clinical workflows, operated by trained professionals in various healthcare settings [5]. Group 3: Company Vision and Future Plans - Nanox aims to drive the transition to preventive healthcare through affordable medical imaging technologies, leveraging AI for smarter diagnostics [7][8]. - The company envisions expanding its technology beyond hospital settings, providing a comprehensive solution from scan to diagnosis [8]. - The Nanox ecosystem includes various components such as Nanox.AI for enhanced imaging analysis and Nanox.CLOUD for data management [9].